CADL Projected Dividend Yield
Candel Therapeutics Inc ( NASDAQ : CADL )Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Co. has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. 20 YEAR PERFORMANCE RESULTS |
CADL Dividend History Detail CADL Dividend News CADL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |